Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Annji Pharmaceutical CoROCO:7754 -3.92%9 PB Ratio is 16.72 as of Jul. 27, 2026, which is 260% above its 10-year median of 4.65. GuruFocus rates ROCO:7754 with a GF Score™ of 9/100. The stock has 3 warning signs investors should review. Among 1,230 Biotechnology companies, Annji Pharmaceutical Co ranks worse than 92.6% on this metric.
The historical rank and industry rank for Annji Pharmaceutical Co's PB Ratio or its related term are showing as below:
ROCO:7754'
s PB Ratio Range Over the Past 10 Years
Min: 2.28 Med: 4.65 Max: 20.12
Current: 16.72
During the past 5 years, Annji Pharmaceutical Co's highest PB Ratio was 20.12. The lowest was 2.28. And the median was 4.65.
ROCO:7754's PB Ratio is ranked worse than 92.6% of 1230
companies
in the Biotechnology industry
Industry Median: 2.785
vs ROCO:7754: 16.72
During the past 12 months, Annji Pharmaceutical Co's average Book Value Per Share Growth Rate was -51.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -14.60% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Annji Pharmaceutical Co was 0.60% per year. The lowest was -14.60% per year. And the median was -7.00% per year.
Back to Basics: PB Ratio
Annji Pharmaceutical Co (ROCO:7754) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7754 vs VRTX, REGN, RVMD: PB Ratio Comparison
For the Biotechnology subindustry, Annji Pharmaceutical Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Annji Pharmaceutical Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Annji Pharmaceutical Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Annji Pharmaceutical Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Annji Pharmaceutical Co (ROCO:7754) has a PB Ratio of 16.72 as of Jul. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Annji Pharmaceutical Co and its competitors. This is 260% above median its historical median of 4.65. Over the past decade, Annji Pharmaceutical Co's PB Ratio has ranged from 2.28 to 20.12. According to the industry distribution chart, Annji Pharmaceutical Co ranks #1139 out of 1230 companies in the Biotechnology industry, placing it in the top 92.6%.
Is Annji Pharmaceutical Co's PB Ratio too high?
Annji Pharmaceutical Co's current PB Ratio of 16.72 is 260% above median its 10-year median of 4.65. Over the past 10 years, this metric has ranged from a low of 2.28 to a high of 20.12. The Biotechnology industry median PB Ratio is 2.79. Annji Pharmaceutical Co's value of 16.72 is 500.4% above this industry median. Based on the distribution chart, Annji Pharmaceutical Co ranks #1139 out of 1230 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Annji Pharmaceutical Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Annji Pharmaceutical Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Annji Pharmaceutical Co ranks #1139 out of 1230 companies for PB Ratio. This places Annji Pharmaceutical Co in the lower half of its industry. The industry median PB Ratio is 2.79. Annji Pharmaceutical Co's value of 16.72 is 500.4% above this benchmark. Historically, Annji Pharmaceutical Co's own PB Ratio has ranged from 2.28 to 20.12 over the past decade. While the company's 10-year median is 4.65 vs. the industry median of 2.79, Annji Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.79, based on 1,230 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Annji Pharmaceutical Co's current PB Ratio of 16.72 is 500.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Annji Pharmaceutical Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Annji Pharmaceutical Co's current PB Ratio is 16.72, which is 260% above median its own 10-year median of 4.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annji Pharmaceutical Co stock overvalued right now?
Annji Pharmaceutical Co (ROCO:7754) has a current PB Ratio of 16.72. The current PB Ratio is 16.72, which is 260% above median its 10-year median of 4.65 and 500.4% above the Biotechnology industry median of 2.79. Annji Pharmaceutical Co's overall GF Score™ is 9/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Annji Pharmaceutical Co (ROCO:7754), the current PB Ratio is 16.72 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Annji Pharmaceutical Co Ltd is an R&D based, clinical-stage new drug company dedicated to the development of first-in-class small molecules focusing on indications with highly unmet needs in the therapeutic areas of neurology, dermatology, and inflammatory disorders, including rare diseases such as idiopathic pulmonary fibrosis and Kennedy's disease, or SBMA (Spinal and bulbar muscular atrophy). Its pipeline products include AJ201, AJ302 and AJ303.
9GF Score
Get the complete analysis for ROCO:7754
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7754 has been successfully added to your 
